The Pharmacy Times® ADHD resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
Studying individuals’ genomes can help influence how different medications work for a patient, avoid harmful adverse drug reactions, and allow scientists to develop personalized medicines for patients with a wide range of diseases and disorders.
Why is a woman being prescribed phentermine for ADHD?
Seventeen million children and adults in the United States are currently living with ADHD. Each October, ADHD Awareness Month is celebrated with different events, activities, and resources to continue shining the light on the disorder.
An analysis of previous studies of children and young adults with ADHD has quantified the extent to which stimulant treatment reduces the development of mood disorders, problems in school, conduct disorders, substance use disorders, and other problems.
The study included an analysis detailing crash and traffic violation records for newly licensed drivers. It is the first large-scale longitudinal study on this topic.
It is critical to stress that Attention-Deficit/Hyperactivity Disorder is probably a lifelong condition for most individuals with the condition.
March 29 Pharmacy Week in Review: Study Evaluates Risk of Psychosis in Young Patients with ADHD, Long-Term Survival May Be Associated with MS Treatment
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
The prescription of stimulants for the treatment of attention deficit-hyperactivity disorder (ADHD) is increasing among adolescents and young adults, and a new study sheds light on possible safety concerns.
The drug's approval was based on 4 clinical studies evaluating the efficacy and safety of Adhansia XR in 883 people who met DSM-5 criteria for ADHD.
Within the group of Spanish patients with ADHD, a specific variation of the LPHN3 gene increased by 40% the risk of nicotine dependence.
Under the settlement and license agreement, Neos has granted Teva the right to manufacture and market its generic version of Cotempla XR-ODT® under the Teva ANDA beginning on July 1, 2026, or earlier under certain circumstances.